Dr. James P. Allison is the chair of Immunology, the executive director of the Immunotherapy Platform, and deputy director for Applied Research of Genitourinary Cancers at the University of Texas MD Anderson Cancer Center.
Dr. Allison, who also serves on the National Cancer Moonshot Blue Ribbon Panel, helped identify the T cell antigen receptor, and discovered that blocking the CTLA-4 receptor on T cells enhances the immune system’s ability to eliminate tumors. This led to the development of the first approved checkpoint immunotherapy, the anti-CTLA-4 ipilimumab.
Among his many awards, Dr. Allison has received the 2015 Lasker-DeBakey Clinical Medical Research Award, the 2005 William B. Coley Award, and the 2013 Lloyd J. Old Award. His current work focuses on deciphering the mechanisms of anti-cancer T cell activity, and figuring out how we can better design T cell-based immunotherapies for patients.
The director of CRI’s Scientific Advisory Council since 2011, Dr. Allison is also a leader of the CRI-SU2C Dream Team, serves on both the Postdoctoral Fellowship Review Committee and CLIP Grant Review Committee, and is a member of CRI’s global clinical investigator network.
CRI plays a very important role in funding the training of young scientists … and helps foster advances in the field that will lead to even more ways to treat cancer down the line.
Let's spread the word about Immunotherapy! Click to share this page with your community.